文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部前列腺癌肿瘤靶向剂量递增:MR引导HDR近距离治疗与整合VMAT推量的剂量学、毒性与生活质量比较

Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
PubMed 文献 · Radiother Oncol · 2020-05-22

两组危及器官剂量和靶区最小剂量相当,HDR组肿瘤平均剂量和最大剂量更高(p<0.05);急性和晚期毒性及生活质量无统计学显著差异,但HDR技术达到更高的肿瘤平均和最大剂量。

要点

  • IB-VMAT与MR引导HDR推量在危及器官剂量学和靶区最小剂量上相当。
  • HDR推量组肿瘤平均剂量和最大剂量显著高于IB-VMAT组(p<0.05)。
  • 两组急性和晚期毒性及生活质量无统计学显著差异。

核心结论

  • IB-VMAT与MR引导HDR推量实现相当的危及器官剂量学、毒性和生活质量结局,但HDR技术获得更高的肿瘤平均和最大剂量。

研究设计与样本

  • 所有患者接受前列腺VMAT 76 Gy/38次,GTV推量分别为IB-VMAT 95 Gy/38次或MR引导HDR单次10 Gy。
  • GTV基于mpMRI勾画并形变配准至计划CT;采用EQD2(假设α/β 3 Gy)进行剂量学比较。
  • 毒性采用CTCAE v4.0评估,生活质量采用IPSS和EPIC量表;中位随访31个月(范围25-48)。

主要发现

  • 两组危及器官剂量和靶区最小剂量相当,HDR组肿瘤平均剂量和最大剂量更高(p<0.05)。
  • 急性G2泌尿生殖毒性IB-VMAT组30%、HDR组37.5%;急性G2胃肠道毒性分别为7.5%和10%。
  • 急性G3事件共3例:泌尿生殖毒性2例(IB-VMAT 1例、HDR 1例),胃肠道毒性1例(IB-VMAT)。
  • 晚期G2泌尿生殖毒性IB-VMAT组25%、HDR组17.5%;晚期G2胃肠道毒性分别为5%和7.5%;晚期G3毒性2例均见于IB-VMAT组(胃肠道1例、泌尿生殖1例)。
  • 两组生活质量无统计学显著差异(p>0.2);两组的泌尿和肠道生活质量域在治疗第6周均显著下降(p<0.05),6个月时恢复基线评分。

关键数值与推荐

  • IB-VMAT推量:前列腺VMAT 76 Gy/38次,GTV推量95 Gy/38次。
  • MR引导HDR推量:前列腺VMAT 76 Gy/38次,GTV单次10 Gy。
  • 剂量学比较采用EQD2,假设α/β 3 Gy。
  • 毒性分级采用CTCAE v4.0;生活质量采用IPSS和EPIC量表。

临床怎么用

  • 对于局限期前列腺癌伴mpMRI可见前列腺内病灶,IB-VMAT或MR引导HDR推量均可作为肿瘤靶向剂量递增的技术选择。
  • HDR推量可获得更高的肿瘤平均和最大剂量,但需结合长期疾病控制数据综合评估。
  • 两种技术的急性和晚期毒性及生活质量结局相当,治疗第6周泌尿和肠道生活质量下降后6个月恢复基线。

局限性

  • 中位随访31个月(范围25-48),长期结局包括疾病控制尚待进一步随访确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report dosimetry, preliminary toxicity and health-related quality of life (HRQoL) outcomes of tumor-targeted dose-escalation delivered by integrated boost volumetric arc therapy (IB-VMAT) or MR-guided HDR brachytherapy (HDR) boost for prostate cancer. MATERIALS AND METHODS: Patients diagnosed with localized prostate cancer, with at least 1 identifiable intraprostatic lesion on multiparametric MRI (mpMRI) were enrolled in a prospective non-randomized phase II study. All patients received VMAT to the prostate alone (76 Gy in 38 fractions) plus a GTV boost: IB-VMAT (95 Gy in 38 fractions) or MR-guided HDR (10 Gy single fraction). GTV was delineated on mpMRI and deformably registered to planning CT scans. Comparative dosimetry using EQD2 assuming α/β 3 Gy was performed. Toxicity and health-related quality of life data (HRQoL) data were collected using CTCAE v.4.0, International Prostate Symptom Score (IPSS) and the Expanded Prostate Index Composite (EPIC). RESULTS: Forty patients received IB-VMAT and 40 HDR boost. Organs at risk and target minimal doses were comparable between the two arms. HDR achieved higher mean and maximal tumor doses (p < 0.05). Median follow-up was 31 months (range 25-48); Acute grade G2 genitourinary (GU) toxicity was 30% and 37.5% in IB-VMAT and HDR boost, while gastrointestinal (GI) toxicity was 7.5% and 10%, respectively. Three patients developed acute G3 events, two GU toxicity (one IB-VMAT and one HDR boost) and one GI (IB-VMAT). Late G2 GU toxicity was 25% and 17.5% in the IB-VMAT and HDR boost arm and G2 GI was 5% and 7.5%, respectively. Two patients, both on the IB-VMAT arm, developed late G3 toxicity: one GI and one GU. No statistically significant difference was found in HRQoL between radiotherapy techniques (p > 0.2). Urinary and bowel HRQoL domains in both groups declined significantly by week 6 of treatment in both arms (p < 0.05) and recovered baseline scores at 6 months. CONCLUSION: Intraprostatic tumor dose escalation using IB-VMAT or MR-guided HDR boost achieved comparable OAR dosimetry, toxicity and HRQOL outcomes, but higher mean and maximal tumor dose were achieved with the HDR technique. Further follow-up will determine long-term outcomes including disease control.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sanmamed N, Lee J, Berlin A, et al. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. Radiother Oncol. 2020. PMID: 32447033. doi:10.1016/j.radonc.2020.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。